In this paper, we evaluate the R&D enhancing effects of two large public grant schemes aiming at encouraging the performance of firms organized in clusters. These are Germany's well known BioRegio and BioProfile contests for which we compare the research performance of winning regions in contrast with non-winning and non-participating comparison regions. We apply Difference-inDifference estimation techniques in a generalized linear model framework, which allows to control for different initial regional conditions in the biotechnology related R&D activity. Our econometric findings support the view that winners generally outperform non-winning participants during the treatment period, thus indicating that exclusive funding as well as the stimulating effect of being a "winner" seems to work in the short-term. In contrast, no indirect impacts stemming from a potential mobilizing effect of the contest approaches have been detected. Also, we find only limited evidence for long-term effects of public R&D grants in the post-treatment period. The results of our analysis remain stable if we additionally augment the model to account for the particular role of spatial dependence in the R&D outcome variables. JEL-Classification: O38, R38, C23
Introduction
Throughout the 1990s, the design of the German national research and development (R&D) policy experienced a paradigmatic shift from standard grant schemes to a regionalization of R&D policy. In this context, the latter principle can be best described as the political concept of providing preferred access to public funding schemes for selected regions, which are expected to yield the highest social return on funding. Since grant allocation according to this rule requires knowledge about the endowment and distribution of regional competencies, so-called contests of cooperation have been established in order to encourage regional actors to jointly participate and signal their common competencies.
Among the first programmes highlighting this competitive spirit were the BioRegio and BioProfile contests starting in 1997 and 1999, respectively. Both programmes aimed to foster commercialization in biotechnology and to make Germany the number one European country in the sector (see Eickelpasch and Fritsch 2005) . The currently ongoing Leading Edge Cluster contest (in German, Spitzencluster-Wettbewerb) of the German Federal Ministry for Research and Education is a prominent successor to this idea, which widens the scope of funding of innovative clusters to other high-tech sectors beside biotechnology.
Although there is by now a huge stock of theoretical and empirical literature on the effects of geographical concentration of the main actors in regional and/or sectoral innovation systems, almost nothing is known about the effects of stimulating the R&D activity in selected regions through such contests of cooperation. In this paper, we thus aim to evaluate the research performance of winners relative to two comparison groups, namely participating (but non-winning) and non-participating regions of the BioRegio and BioProfile contests, for the periods during and after funding. As outcome variables of interest, we analyse the regions' patenting activity and their expected ability to raise public R&D funds due to the status of being a 'winner' in the respective contest.
1 Our database covers all 426 German NUTS-3 districts (Kreise) for the period 1991 to 2007. From a methodological point of view, we estimate a set of Difference-in-Difference (DiD) models based on Poisson and Zero-inflated Poisson regressions, where the latter account for excessive zeros in the outcome variable (in particular: the number of research projects raised through public funding, as well as the number of patent applications for all German NUTS-3 districts). To account for the likely role of spatial dependence in the dataset, we also apply spatial filtering techniques to the model in a robustness check.
The remainder of the paper is structured as follows. In section 2 we briefly discuss the theoretical background. Section 3 sketches the database, and presents several descriptive findings, followed by a brief summary of the estimation strategy. The estimation results are discussed in Section 4. Section 5 reports the outcome of the augmented modelling approach, which additionally controls for spatial dependence in the outcome variable. Finally, Section 6 concludes the paper.
2 The regionalization of R&D policy
Rationales
The R&D regionalization policy described above fits quite closely with the theoretical expectation that the extent of externalities, technological change and commercialization of innovative ideas are all positively affected by the geographical concentration of public and private research actors who share interests in similar fields of technology. 2 The positive effects of local agglomerations have their roots in Marshall's (1890) externalities based on specialized labour pools, input sharing and knowledge spillovers. Since biotechnology is a dynamic research field, new scientific insights into technologies and procedures are vital to a firm's survival and success. Therefore, access to talented and well-trained scientists like postgraduate students and laboratory personnel is of particular importance. Almeida and Kolgut (1999) show that regional agglomeration of knowledge both intra-and intersectorally ("knowledge clusters"), access to scientific facilities, and a suitably trained labour pool may be favourable for firms. Entrepreneurs of biotechnological ventures who are embedded in these networks have the chance to take advantage of access to knowledge, financial institutions, and so on. While the positive effects of local agglomerations for knowledge intensive industries might be clear from a theoretical point of view, it is not easy to identify the causal effect of geographical proximity on R&D activity. Starting from the influential work of Acs et al. (1993) , Jaffe et al. (1993) , Audretsch and Feldman (1996) and Anselin et al. (1997) , there is a growing literature aiming to empirically test the transmission channels from clustered firms to enhanced R&D and innovation activity and finally productivity growth. Acs et al. (1993) , for instance, estimate production functions for US data and find that, beside standard input factors, the geographical position in a cluster matters strongly. Jaffe et al. (1993) find that patent applications are cited to a greater extent by actors in geographical proximity to the inventor rather than from actors far away from inventors. Likewise, Baptista and Swann (1998) , based on UK micro data, show that firms in sectors that show a geographical concentration indeed exhibit, on average, more intensive research activities. In a further study, Baptista (2000) shows that firms adopt technical innovations particularly in those regions which are characterized by a high share of firms having implemented the same innovations already. With respect to Germany, Dauth (2010) , among others, finds empirical evidence that the existence of industrial agglomerations is significantly correlated with higher regional employment growth rates, compared to regions which are not clustered.
The main question remains how to interpret such findings. For example, Baptista (2000, p. 529) states: "... [o] ne can, therefore, claim that there are significant learning effects arising from the geographical proximity to previous adopters". In fact, it is quite probable that learning effects are higher in local agglomerations due to the existence of firms with higher knowledge competencies and absorptive capacities. One may then assume that local agglomerations are characterized by a "selection of the fittest", that is, actors with research activities and knowledge competencies above average prefer geographical proximity to actors with similar skills. Studies by Zucker et al. (2006) and Klepper (2007) clearly support this view. Klepper (2007) , for instance, argues that betterperforming firms will have more and better spinoffs, and these spinoffs will generally locate close to their parents. Zucker et al. (2006) are able to show that scientific stars become more geographically concentrated over time because of relocations from areas with relatively few peers to those with many actors in their field of expertise. If selection of the fittest works, then geographical proximity between well-performing actors might indeed be useful for knowledge transfer. However, so far empirical research has not tackled this puzzle clearly.
To sum up, higher economic outcomes of local agglomerations based on the selection of the fittest, geographical proximity, and the interplay between both driving forces seem to matter for R&D activities. These insights are essential for understanding any potential effect stemming from a regionalized, cluster-oriented R&D policy. The funding of projects in such leading-edge local agglomerations might have larger outcomes due to the acquisition of outside money, and higher effectiveness based on the selection of the fittest and the geographical proximity between well-performing actors.
Cluster-oriented R&D policy and its evaluation
The BioRegio contest (BRC) marks a major milestone of the German Federal Government's policy to stimulate the transfer of new knowledge into new products and thereby narrow the gap between Germany and those countries leading in the application of biotech-nological knowledge, i.e. the USA and Great Britain. The BRC was initiated by the Federal Ministry of Education and Research (BMBF) in 1995 and encouraged regions to apply for subsidies to be used in establishing a biotech industry in the region (Dohse 2000) . The funding concept aimed at developing a new holistic approach for R&D and innovation policy and was planned to integrate biotechnological capacities and scientific, economic and administrative activities. The governmental purpose of funding biotechnology was -and still is -for the German field of life sciences to catch up with the high international standard of performance. From the political perspective there should be a direct R&D and output enhancing effect of the exclusive funding for winning regions as well as additionally a reputation effect. Moreover, further indirect effects may be expected from the approach. These can potentially arise for non-winning participants due to a mobilization effect of the contest, that is, regions which have organized themselves and formulated a common strategy can use these efforts as a future asset even without receiving financial benefits. Indirect effects thus mean to push developing strategies and financial backing at all locations in Germany with a critical mass in biotech research.
In sum, 17 BioRegions were formed and participated in the BRC. An independent jury selected four winning regions (Rhineland, Rhine-Neckar, Munich, and Jena with special vote) out of a total of 17 participant "meso"-regions (clearly exceeding the size of NUTS-3 districts). Major criteria were based on "hard" facts like the existence of a critical mass of biotech firms and research facilities within the region, regarding the absolute number of firms, the average firm size, and the firms' R&D and economic performance (for details, see Dohse, 2000) . Each winning region received a total amount of public grants of about 25 Mio. (exception Jena: 15 Mio.) to conduct R&D-projects. Additionally, winning regions were favoured in terms of getting access to the standard R&D-grant schemes of the BMBF. The total amount of these grants was about 750 Mio. Participation in the BRC and BPC was thus attractive in order to receive additional subsidies and to attract actors within the region and outside the region for participation in biotech-related research projects. It also offered access to different valuable resources which could give rise to increasing knowledge competencies, accelerating the commercialization of biotechnology-related products.
Despite its growing political importance, there are only very few quantitative studies that aim to measure the success of cluster-oriented R&D policies. Looking at the international evidence, Martin et al. (2010) were among the first scholars to apply a quantitative (DiD) approach to the evaluation of economic effects of the French "Local Productivity System" (LPS) cluster programme. A further analysis for the subsequent French Policy of "Competitiveness Clusters" has been conducted by Fontagne et al. (2010) , mainly finding that the policy was effective in picking the winners. With respect to German data, Falck et al. (2010) use a similar estimation strategy in order to analyse a regional innovative cluster policy for Bavaria. While Martin et al. (2010) do not find evidence of productivity advantages of the specific cluster policy; Falck et al. (2010) conclude that the Bavarian state-wide cluster policy led to a significant increase in the probability of being innovative for Bavarian targeted sector relative to non-Bavarian targeted sectors and Bavarian non-targeted sectors (two comparison groups). In fact, the Bavarian State Government provided an amount of 1.45 billion for R&D projects to Bavarian firms and research institutes, which comes close to typical funding schemes at the Federal government level.
While several earlier papers (e.g., Czarnitzki et al. 2007 ) already pointed out that R&D funding positively affects R&D activities of the grant recipients, the findings of Falck et al. (2010) are clearly in line with this strand of literature and additionally add further insights with respect to the role of financial support explicitly designed to support the research effort of innovative clusters. From the viewpoint of public authorities, it is desirable to know whether cluster-oriented funding schemes imply greater outcomes compared to individual funding, and to know how clusters perform after the funding period.
Specific to the biotechnology sector, different studies have both analysed the role of clustering as well as public funding. Using a global dataset for 59 consolidated biotechnological firms, Lecocq et al. (2009) Looking at policy effects, recently Cooke et al. (2007) compared several measures for the success of policy support in the biotechnology sector (e.g., number of biotech firms, products in pipeline). The authors find that BRC as well as BPC winners perform better than non-funded biotech regions. However, the authors do not differentiate between non-winning participants and non-participants within the group of non-funded biotech regions. In doing so, Engel and Heneric (2008) find that non-winning participants of BRC outperform winning and non-participants regions of BRC with respect to the change in the number of newly founded biotech-firms between 1995-1998 and 1999-2003 . Thus, the authors conclude that the certification as winner and exclusive financial support do not matter in attracting new biotech firms, compared to other participants.
A shortcoming of both studies is that the authors do not address the evolution of BRC winning regions after the funding period. Using actual data for the total amount of public R&D funds raised, we take up this research question explicitly. While many studies point out that public funding implies higher R&D activity of firms, we are explicitly interested to know whether path dependence matters for the acquisition of R&D funding. Furthermore, we will provide empirical evidence on whether BRC and BPC winning regions were more successful in terms of patent applications during the funding period.
3 Data and empirical estimation strategy
Data and variable definition
In the following, we give a short description of the variables employed to analyse the effects of the BRC and BPC at the level of the 426 German NUTS-3 districts. Several databases are needed to analyse the regional structure of Federal support for biotechnology projects and its determinants. In detail, we link the following data sources (see table 1):
• Patent data from the European Patent Office (EPO), namely "ESPACE" Bulletin,
• Socio-Economic data from various sources including Federal Agency for Labour, ZEW Foundation Panel, as well as the Federal Statistical Office.
The PROFI database covers the civilian R&D funding of the German Federal Government. For the purpose of this paper, we focus on direct funding of biotechnology-related projects. The database contains information on the number of projects, expenditures, name and address of recipients, type of project (individual versus collaborative projects), and so on.
3 Based on the "ESPACE" Bulletin, we extract information regarding patenting behavior. Patent applications are the most important measure of innovative capacity (see e.g. Griliches, 1990 , for comprehensive discussions on the informative value of patents). We measure patent applications in the technology field "biotechnology" at the location of inventors, and add up the number of patent application per county when at least one inventor comes from this county. Acquisition of public funding and patent applications as outcome variables are determined by the innovative capacity in the region. In order to minimize any bias stemming from time-varying omitted variables, our set of explanatory variables thus considers, within the set of regressors, several aspects of the districts' innovative capacity, which are extracted from several databases. Among others, R&D employment data, defined as the share of employees trained in mathematics, engineering and natural sciences relative to total employment, and obtained from the Federal Employment Agency, are used to extract measures regarding the innovative capacity of counties. We add further research activity specific measures like firm-specific information in the manufacturing sector (export share, firm size etc.) and start-up activity in high-tech industries. The latter critical variable measures the entrepreneurial climate and thus, the potential to commercialize innovative ideas via the channel of creating a new business. Finally, we also include measures for the regional patterns in sectoral specialization and agglomeration in general. The latter variable is proxied by employment in sectors with a high Ellison-Glaeser-Index (> 0.005) relative to total employment in the region. 4 This measure, in turn, may provide general information about the Marshallian forces at work at the NUTS-3 level (that is, forward-backward linkages, labour market pooling and knowledge spillovers). A detailed description of the data definitions is given in Table 1 .
For the empirical analysis we collapse the yearly observations from our sample data into three periods: 1.) Pre-treatment period, 2.) treatment period and 3.) post-treatment period. The time span of each period differs for BRC and BPC due to the fact that BPC ran two years after BRC (see Table 2 ). Therefore we prepare two samples, one for the evaluation of BRC and the other one for the evaluation of BPC. The first BRC sample contains BRC winners, non-winning participants and non-participants.
5 While non-winning participants are needed as comparison group to assess the likely direct effects the respective regions; we use the number of raised research projects rather than the financial volume. The correlation of both indicators is reasonably high (Pearson's correlation coefficient is 0.87 for all projects and 0.91 for cooperative R&D projects), so that the number of projects serve as a good substitute for the financial volume. This strategy also avoids to put strong assumptions on the annual streams of funding over the project period. of funding, non-participating regions serve as second comparison group (both relative to winners and non-winners) in order to give a first quantification of the possible indirect effects of funding as outlined above. We exclude BPC winners from the group of nonwinning participants in this sample since BPC winners partly also received funding during the BRC. This exclusion might be critical given that the BPC winners are an ideal control group for BRC winners since we do not face the problem of self-selection into the treatment here. Both groups only differ with respect to the timing of exclusive funding and the label "winner". Therefore, we prepare a second BRC subsample (labeled BRC2) to improve the similarity between the treatment and the comparison group. This approach has the disadvantage of shortening the investigation period. While many R&D projects started immediately after the announcement of "BRC winner" we believe that losing two years does not fundamentally affect the precision of our estimates. Descriptive statistics of the samples according to Table 2 are given in the Appendix. Although collapsing the yearly observations into three time periods results in a loss of information, there are also statistical reasons that advocate carrying out the DiD estimation strategy this way. Bertrand et al. (2004) , for instance, propose to collapse data with a long sample range into just two periods (one before and one after the policy intervention) in order to minimize the risk of obtaining underestimated standard errors due to serially correlated errors when unobservable factors are present over time. Since knowledge production in biotechnology is a complex issue (i.e., is difficult to model adequately), correlation of errors can be expected over cross-sections, which makes collapsing the dataset into three periods a reasonable empirical estimation strategy. Additionally, certain variables such as start-up activity are only available at longer time intervals, so that the decision of collapsing the data is also a practical issue. For the outcome variables, we sum up the number of patents and publicly funded projects observed for each region for the time intervals defined in Table 2 . For the set of explanatory variables, we use sample averages for each respective time period. Table 3 shows that both the number of directly funded projects and the sum of allocated grants in the field of biotechnology increased significantly between 1991 and 2007. In particular, we observe a take-off in the figures between the periods 1991-1996 and 1997-2002, which may give a first indication of the boost in Biotech funds throughout the BRC competition. Compared to this, for the period 2003-2007 we observe a consolidation phase of public R&D spendings to biotechnology. The apparent time trend faced by the whole industry makes it thus important not only to compare the performance of winner regions over time but also relative to the other actors in order not to erroneously allot the positive industry trend to the causal impact of BRC (and BPC) funding. Table 4 and Table 5 show the allocation of federal funds with respect to the different regions, and the share of cooperative R&D projects, respectively. Table 4 points out that BRC winners could increase their relative share of allocated fund during the treatment period 1997 to 2002 even further. However, for the post-treatment period, we see a significant bump in the regional share of total direct project funds. On the contrary, nonwinning BRC participants were able to significantly increase their share. The same applies for BPC winners and other (non-participating) NUTS-3 districts. Moreover, BRC winners face a relative reduction in their share for the post-treatment period, which turns out to be lower compared to their pre-treatment share. This observation may give rise to the hypothesis that the exclusive funding follows the rationales of time-limited commitments to push the evolution of regions further. Finally, the table shows that, in absolute terms, the different treatment and comparison groups appear to have received a fairly similar share of funding indicating that they may serve as homogeneous comparison groups with respect to the outcome variable of publicly funded R&D projects. Finally, Table 5 further highlights that, for all regions, the share of cooperative R&D projects increased over time. It seems that exclusive funding for "winners" correlates with the extension of collaborative projects. BRC and BPC winners show a significant increase in the share of collaborative projects during the treatment period (1997-2002 for BRC and 2001-2007 for BPC). Most interesting, the importance of collaborative projects (as share of overall projects) reduces for BRC winners in the post-treatment period. Given the fact that patenting activity inherently exhibits a time lag in the transmission process from R&D funds to R&D activity and finally R&D outcome, in this paper we are only able to compare the treatment effect relative to the pre-treatment period for winning regions of the BRC/BPC with the specific comparison groups. Due to restrictions in patent data publication, as well as time lags in the transmission from R&D inputs to outputs, we cannot construct a sufficiently long post-treatment period. Thus, for patent applications, we set the treatment and pre-treatment periods as follows: from 1991 to 1997, we assume that there is -by definition-no significant patent application activity as a result of the BRC. Instead, for the period 1998 to 2006, we assume that patent applications are directly influenced by the BRC (2002-2006 for the BPC). As Table 6 shows, BRC winning regions significantly increased their number of patents in the treatment period. The growth rate was about +183 %. However, also BPC winners showed a significant boost in their patenting activity (+281 %), showing the strongest growth performance among all four groups. Compared to BRC winners Table 6 shows that BPC winners were initially smaller in absolute size, but showed a convergence to the BRC level throughout the sample period. For the non-winning participants, as well as for all remaining NUTS-3 districts, the number of patent applications showed a smaller increase (+93 % and +168 %, respectively). Finally, compared to public R&D spendings from Table 6 , we also see that here the inter-group heterogeneity is much higher, indicating that especially the comparison between winning and participant regions is expected to yield the utmost reliable results in the estimation approach trying to minimizing any possible self-selection bias. We turn to the model setup in the following. 
Model setup
As outlined above, in order to carefully analyse the effects of funding on private R&D activity, we have to estimate a set of models which differs by the design of the treatment versus the comparison group and the time period employed, as shown in Table 2 . The econometric literature offers different approaches how to estimate treatment effects. Here we apply a Difference-in-Difference (DiD) techniques, which aims at isolating the policy related effect related to changes in the outcome variable Y i,t for a group of treated individuals (i, in our case: NUTS-3 regions) over time (t, in our case: limited to two consequtive periods) relative to a comparison group. The underlying assumption of this approach is that the difference between the treatment and comparison groups would have been constant over time if the treatment group had not received the subsidy. Since we are dealing with three groups (winners, participants and non-participants), our model specification has the following general form
where D 
Thus, the third group of non-participating regions serve as the benchmark case, for which we do not include a separate dummy variable in the regression equation. Statistically significant positive parameters for D Statistically significant parameters δ 1 and δ 2 indicate a positive treatment effect for each subgroup relative to the benchmark case of non-participant regions.
6 They can be interpreted as the combined direct and indirect effects of funding, respectively. By testing for parameter restrictions in terms of δ 3 = (δ 1 − δ 2 ), we are finally able to identify the treatment effect of winners versus non-winners within only single regression exercise, which allows us to isolate the direct treatment effect of funding. In other words, the latter can be defined as a difference in the difference-in-difference (DiDiD) parameter. As argued above, we are especially interested in this parameter since the risk of inducing a self-selection bias is smaller for this comparison setup. This model setup has the advantage that it does not lose its validity in case of time-invariant omitted variables. However, it is sensitive to temporary fluctuations that may influence the performance of the treatment and control groups differently. The latter problem can be handled by including a set of time-varying control variables (X) for further regional characteristics, like the number of firms, new firm formations, the international competiveness, share of R&D employees, sectoral specialization and agglomeration. u i,t is the error term of the model and α, β 1 , β 2 , γ and ω are further regression coefficients.
Since we are dealing with patent and R&D grants count data that exhibits a high share of zeros, the underlying distribution of the outcome variables may be non-normal distributed, nor conforming to a regular or overdispersed Poisson. A common solution to this problem is to rely on a so-called zero-inflated Poisson (ZIP) model, which assumes different data generating processes are in order to predict the general probability of regional R&D activity in terms of a binary choice model (Probit or Logit specification) and its actual (non-zero) size estimated by means of standard Poisson model. For our estimation approach, we explicitly test for the appropriateness of the ZIP specification versus the standard Poisson model by means of standard postestimation tests.
Moreover, a crucial point for our empirical policy analysis is whether the estimated DiD parameters in the (non-linear) ZIP model can be interpreted in the usual (linear) fashion. For the case of the Poisson model, the answer is straightforward, since the latter is just a flexible generalization of the ordinary least squares regression. In other words, we are still in the linear case and the usual assumptions hold. Since the Poisson model uses the logarithm as the link function, we can obtain the marginal effect for the DiD parameter as [exp(δ) − 1].
In contrast to this, Ai and Norton (2003) have recently argued that, if the DiD term is included in the non-linear Probit/Logit part of the model, interaction terms have to be analysed with caution, since both the reported significance and their qualitative interpretation may be misleading. On the other hand, Puhani (2008) has shown that the DiD interaction term in non-linear models can still be interpreted in the same way as the linear case, as long as the model has a strictly monotonic transformation function.
7 This latter condition holds both for the Probit as well as the Logit specification. Irrespectively of this debate, for the research question at hand, it turns up to be more convenient including the DiD term only in the Poisson part rather than the non-linear Probit/Logit specification. This decision can be motivated by the argument already given above that both the BRC and BPC aim to improve the track record of promising biotech regions rather than initiating a regime switch from non-innovators to innovators.
Estimation results
In this section we estimate different ZIP models for the samples designed according to table 2. Statistical inference for the two DiD terms is made directly from the regression output, significance of the DiDiD term is tested ex-post based on the so-called delta method (for details, see Greene 2003 ). As argued above, while the comparison of participants in a broad sense (that is, both winning and non-winning regions) relative to other NUTS-3 districts serves as a first indicator for policy effectiveness, the comparison of programme winners relative to non-winning but participating regions allows in particular to answer the question of whether the proclamation of the contests itself was a signal strong enough to encourage R&D networks, or whether actual extra funding was necessary in order to boost R&D activity in the short and medium run. In all empirical specifications, we include a broad set of regional control variables (X), as listed in Table 1 . The main empirical results regarding the parameter of the DiD term for different sample designs are given in Table 8 . Full regression outputs are reported in Table 8 to Table 9 . Tables 8-11 .
As Panel A.1 in Table 7 (for the BRC) shows, we detect a positive and statistically significant higher number of patent application and raised R&D projects for BRC winners compared to non-participants throughout the treatment period. Likewise, the result holds for all R&D projects, as well as for the sub-group of collaborative R&D projects. These findings clearly support the existence of direct treatment effects of funding, and suggest that the label "winner" signals an above-average R&D performance as well as may contribute positively to a better innovative performance in biotechnology. However, we do not find evidence of indirect effects of funding when analysing the estimated DiD term parameters in Panel A.1. That is, we do not find any statistically significant effect with respect to publicly funded R&D project allocation when comparing the performance of non-winning regions with the non-participating comparison group. For patents Table  7 even reports negative results.
The drawback to the approach in Panel A.1 is that one may still argue that BRC winners differ from remaining regions with respect to adjustments due to environmental changes. 8 The implementation, in April 1997, of the "Neuer Markt", Germany's equivalent to the United States' NASDAQ, and its rapid growth measured by the number of listed companies and market capitalization, marks a remarkable change. While highly profitable exit opportunities are offered to investors in non-listed firms, venture capital investments in biotechnology went up by a factor of six between 1997 and 2001 (see OECD 2006: 119). According to the "selection of the fittest"-hypothesis, firms and scientists in BRC winning regions are more stimulated by the rapid growth of the venture capital market. As a result, inventions could be better protected by patent applications to secure a unique selling proposition in the commercialization process of innovative ideas. However, comparing BRC winners with BPC winners (as a comparison group in BRC2) may be seen as an effective strategy to eliminate some of above-mentioned differences in adjustments to temporary shocks. In detail, the share of venture capital-financed firms does not differ remarkably between BRC and BPC winners (see Engel and Heneric 2005) . To account for these structural differences, in Panel A.2 we report the estimation results of the BRC2 sample, where we compare the relative performance of BRC winners against the one of non-winning participants, including BPC winners, prior to the starting date of the latter competition. The results for patent applications show that BRC winners again show a better track record compared to the remaining full candidate set for the treatment period (1998 -2002), both in terms of patent applications and of the number of raised R&D projects. However, if we split the latter candidate set into BPC winners and remaining participants, we see that the obtained positive direct treatment effect of BRC winners for patent applications stems mainly for the relative track record of winners relative to non-winners (net of BPC winners). Compared to them, BPC winners show a better patent performance, while they clearly fall behind in terms of raising R&D funds.
Given the absence of direct effects (or even negative ones) for patent activity between BRC and BPC winners, one may thus raise the question of whether the selection mechanism in the BRC competition was operating poorly. However, in order to answer such question, one has recall that the goal of the programme was to push the technological competitiveness of German biotechnology towards an international dimension. As the regression parameters for the dummy variables in Table 8 show, the level of BRC winners was more than twice as large as the reference group, while BPC winners were only 1.2 times larger in terms of patent applications. Thus, among the positively performing candidates, the jury clearly picked the heavyweights, compared to the dynamically growing -but smaller -'rising stars'. The latter were actually selected in the second stage, the BPC. This finding provides further empirical evidence that both the BRC and BPC are a sequential result of "picking the winners" as argued, for example, by Dohse (2000) .
In search of long-term effects of BRC participation and exclusive funding, we present, in Panel B, findings for the R&D performance of BRC winners and the comparison groups in the post-treatment period. This comparison may give an indication of which new equilibrium levels will be reached after the extensive funding by the BRC. On the one hand, we may expect that receiving additional public funding allows competence building, and thus, positive path dependence should matter. On the other hand, the number of raised public R&D grants may actually follow different motives than allocating R&D facilities to the most successful region (e.g., distributive rather than allocative arguments from a policy perspective). As the results in Table 7 show, in comparison with the shortterm effects in the treatment period, statistical evidence for long-term effects of funding is indeed much weaker. Although BRC winners still tend to outperform non-winners with respect to raised public R&D funds, there is no evidence of an overall better performance compared to non-participating regions, and non-winners even appear to fall behind the reference group of non-participating regions.
Compared to non-participating regions, the only significant difference of BRC winners is their ability to raise more collaborative projects. This result hints at the successful network creation resulting from the funding period. We do not find statistically significant long-term effects comparing non-winning participants and other regions. This latter result may point to the fact that the number of biotech regions has grown over time and, likewise, to their attempts to increase the propensity their success rate in the acquisition of R&D grants. BRC non-winners and non-participants have significantly improved their position relative to BRC winners. As a matter of fact, ten more BioRegios were formed by 2005 (for details, see Engel and Heneric 2005) . In addition to the efforts of the Federal Government, many Federal States governments promote BioRegios within the state. At this stage, we cannot fairly conclude that regionalized technological policy lacks efficiency in the long term. We believe that improvements in -particularly -non-participants are the key explanation for the absence of long-term effects of BRC.
Finally, switching to the evaluation of the BPC, Panel C shows the findings for BPC winners and the two comparison groups. Consistently with the findings discussed above, here we obtain fairly small effects when comparing winning and other regions, as the winners only appear to perform better in terms of raising collaborative R&D projects. Nevertheless, the "selection of the fittest" also seems to works in both stages of the competitions, since the BPC winners also perform significantly better than non-winning participants during the treatment period for the latter contest. The estimated elasticity of the DiD term is about the same size as the effect identified for the BRC. This is an important finding, since one might expect the performance of the winners at the second stage to be characterized by lower differences with the non-winners. The smaller treatment effects found for BPC winners relative to non-participants may be partly due the consolidation phase going on in the industry throughout the second half of the last decade. Although we control for a common time trend among all groups, which turns out to be significantly negative according to Table 8 , throughout this consolidation period the chances to realize excess returns for funded regions may also have been limited.
We finally report some details about our estimation setup according to Tables 8-11 . Regarding the appropriate functional form, in most specifications the ZIP model is favoured over the Poisson model based on information criteria (AIC, BIC) as well as on the Vuong (1989) non-nested test for the Poisson and ZIP model. A significant test statistic indicates that the zero-inflated model fits the data better. To highlight the likely differences between the standard Poisson and the ZIP model, Figure 1 additionally plots the in-sample forecast error of the Poisson (PRM) and ZIP model for the observations close to zero in the patent model (BRC participants versus other districts). The figure shows that the ZIP is superior to the PRM in all predictions, in particular for values close to zero. As a key explanatory variable in the Probit specification, we use the share of regional hightech startups as an indicator of the innovative climate for a region that either supports R&D or not. In all specifications, this variable turns out to be statistically significant and of the expected sign. Also, the remaining variables in the Poisson part of the model mostly reflect our ex-ante expectations: that is, both the share of R&D employees and the export share have a positive impact on R&D activity. Moreover, the total number of firms, the variables measuring general agglomeration (e.g., population density), and sectoral concentration indices (and their squared values) are statistically significant. In this section, we aim to investigate the role played by spatial autocorrelation (SAC) in our empirical models. Recently, Grimpe and Patuelli (2010) have shown, for the case of the German nanomaterials sector, that SAC may be highly relevant in the estimation of NUTS-3-level regional knowledge production functions using patents as a dependent variable. According to Cliff & Ord (1981) SAC can be defined as the correlation among observations of a georeferenced variable stemming from to their direct proximity. SAC may be due to self-correlation, omitted/unobserved variables, or spatial spillover effects. Disregarding cross sectional dependence in the data may indeed lead to biased estimation results (Anselin 1988 ) and therefore to inappropriate model interpretation. In line with Grimpe and Patuelli (2010), we thus include an eigenvector-based spatial filter in our models, in order to account for the potentially uneven -and spatially correlated -regional distribution of biotech activities in Germany. Hence, the spatial filter can also be seen as a surrogate for unobserved fixed effects and its inclusion may limit the bias stemming from omitted variables (Patuelli et al. 2009 ).
The advantage of spatial filtering with respect to other spatial regression techniques is that the spatial filtering approach does not require an assumption of normality or other estimation restrictions, and can be straightforwardly applied to regression equations with any underlying distribution (including Logit/Probit and Poisson regression). We use an approach developed by Griffith (2000 Griffith ( , 2003 , which makes use of the commonly known Moran's I (MI) statistic.
9 The latter is defined as an indicator of the average spatial association, between N cross-sectional units, for variable y and on the basis of the elements w of a spatial weights matrix W , according to:
where
w ij is a measure of the overall connectivity of the geographical system, andȳ = The simplest -and often effective -strategy is to use a binary spatial weights matrix where a (i, j) unit takes the value of 1 if a certain criterion for spatial proximity between cross-sectional units i and j is fulfilled, and zero otherwise. One standard way is to choose common geographical borders as a geographical discrimination criterion, but the choice is not limited to this dimension.
To get a first indication about the role played by spatial dependence for our two outcome measures, in Table 12 we compute the corresponding Moran's I values based on a border based spatial neighbourhood matrix.
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Interestingly, while the regional distribution of patent applications indeed shows positive spatial autocorrelation, the regional distribution of publicly funded research projects does not exhibit any particular spatial pattern (both for the aggregate number and for the subgroup of collaborative projects). The latter results may be seen as a further hint to the strong distributive element included in the allocation of public projects. Having shown that spatial dependence is highly present in the patent data model, we finally reestimate the model based on the three samples (BRC1, BRC2, BPC). We are particularly interested to see whether the results obtained from the aspatial analysis hold once we include a set of MI-based spatial filters. The approach extracts orthogonal and uncorrelated numerical components (eigenvectors) from the projection matrix of the exogenously specified spatial weights matrix W. 11 The extracted eigenvectors represent all possible patterns of latent spatial autocorrelation implied by the chosen form of W. The latter has to be first transformed according to:
where I is an (N × N ) identity matrix, and 1 is an (N × 1) vector containing ones. The extraction according to Eq.(5) then gives a set of N eigenvectors (e i with i =, 1 . . . , N ), which have the properties of maximizing SAC, while being orthogonal to the previously extracted eigenvectors. To reduce the total number of included eigenvectors in the regression equation, we follow Grimpe and Patuelli (2010) and first select a subset of candidate eigenvectors according to the following threshold: M I(e i )/max i [M I(e i )] > 0.25, where M I(e i ) is the MI computed on a generic eigenvector i.
12 A graphical presentation of the regional distribution of biotechnology patent applications for 1991-1997 and 1998-2006, as well as the first two extracted candidate eigenvectors (E1, E2) is given in Figure 2 . The candidate set is then included in the regression model and a stepwise estimation approach is carried out, starting from the full model specification and subsequently excluding non-significant eigenvectors while model-based variables are kept as part of the minimum model. 13 The results in Table 13 show that the included eigenvectors are 
Conclusion
In this paper, we analysed the performance of winning regions of Germany's well-known BioRegio and BioProfile contests. These contests marked a milestone in the attempt to allocate public R&D funds in a competitive way, which strongly emphasizes the role of geographic proximity in knowledge creation, and to push collaborative R&D projects in leading biotechnology clusters. Although the BioRegio contest was one of the major attempts of the German Federal Government to narrow the gap between with those countries leading in the application of biotechnological knowledge, so far little is known about its innovation and economic impact during the treatment period and in the posttreatment period. We tackled this issue by analysing two important measures of R&D performance, namely, the number of patent applications in biotechnology, and the number of publicly funded R&D projects. We applied a Difference-in-Difference estimation within a generalized linear model framework, based on data for 426 German NUTS-3 districts. Our estimation strategy allows to control for observable and time-invariant unobservable differences in the pre-funding period, which also drive R&D performance in the treatment and post-treatment period. In order to identify the effect of the BioRegio and BioProfile contests on regional R&D activity in the field of biotechnology, we evaluate, in first place, the research outcomes of winning regions against non-winning participants. The choice of this first comparison is motivated by the need to reduce the potential self-selection bias stemming from a nonrandom selection into treatment. Our results show that BRC winners and (to a lesser extent) BPC winners outperform non-winning participants during the treatment period. Exclusive funding, as well as stimulating effects of the "winner" label, seems to work for them in the short run. Given the sequential starting dates of the BioRegio and BioProfile contests, we are also able to compare the performance of BRC and BPC winners during a limited treatment period. In this case, the results highlight two empirical facts: on the on hand, after being selected, the BRC winners significantly increased their relative performance in raising public R&D projects; on the other hand, they do not outperform BPC winners in terms of patent applications during the treatment period, although both groups show a significant positive effect compared to non-winning participants (in both competitions). The catching up of BPC winners to BRC winners can be explained in particular by their smaller absolute size in terms of the number of patent applications prior to the treatment, for which we control in our Difference-in-Difference approach. Thus, among the candidates in the BRC, the jury clearly picked heavyweights, compared to the dynamically growing, but smaller 'rising stars'. The latter were selected in the second stage, namely the BPC. This finding provides further empirical evidence that the outcome of both the BRC and BPC are the obvious result of "picking the winners", as argued, for example, by Dohse (2000) .
In contrast with these positive effects during the treatment period, we do not find significant outcome effects of public R&D grants for BRC winners in the post-treatment period. This result is striking, and may indicate that the success of the BRC seems to be only of a temporary manner. However, there is some evidence of positive longterm effects for collaborative R&D projects. Moreover, the reader has to note that our findings may be limited by the quality of the indicator used: in fact, we are only able to compare the number of raised public R&D grants, which may actually follow different allocation guidelines than the one of serving the most successful regions (e.g., distributive arguments). This result is also supported by the analysis of the spatial distribution of the outcome variables. Finally, the absence of long-term effects of BRC may also driven by the fact that non-winning regions have increased their efforts to establish networks between biotech-related firms and research units. In fact, ten more BioRegios were formed by 2005 after the BioRegio contest, and several Federal States have promoted significantly the emergence of BioRegions locally. These efforts are clearly intended in the contest of a cooperation approach to R&D policy.
Future analyses will thus be needed to consider additional market-related measures for R&D performance assessment (e.g., the share of turnover with new biotech products, or employment in biotechnology-related firms). These further indicators will allow academic research to provide more thorough assessments of the success rate of cluster-based R&D policies, which are currently widely applied at the national and regional level.
